SCHEMBL5334482

SCHEMBL5334482

CCN(CC)Cc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MC4R P32245 2/20 0.49
GAA P10253 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
CKS1B P61024 2/20 0.47
SKP1 P63208 2/20 0.47
SKP2 Q13309 2/20 0.47
GPR119 Q8TDV5 1/20 0.45
SMARCA2 P51531 1/20 0.45
SMARCA4 P51532 1/20 0.45
PBRM1 Q86U86 1/20 0.45
ACHE P22303 2/20 0.45
CHRM2 P08172 1/20 0.45
CHRM4 P08173 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 1/20 0.44
NAMPT P43490 1/20 0.44
BACE1 P56817 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5336618 0.89 GAA (0.44) GAASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL7981893 0.88 GAA (0.56) GAASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL4511470 0.88 GPR119 (0.50) MC4RGAASMN1; SMN2CKS1BSKP1
SCHEMBL5333002 0.87 CKS1B (0.47) MC4RGAASMN1; SMN2CKS1BSKP1
SCHEMBL5333142 0.85 SMN1; SMN2 (0.44) MC4RGAASMN1; SMN2CKS1BSKP1
SCHEMBL28708137 0.85 GPR119 (0.49) GAASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL5336420 0.84 MC4R (0.45) MC4RGAASMN1; SMN2CKS1BSKP1
SCHEMBL14387740 0.84 GPR119 (0.44) GAASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL7986047 0.84 CKS1B (0.57) GAASMN1; SMN2CKS1BSKP1SKP2
SCHEMBL5338217 0.83 CKS1B (0.50) MC4RGAASMN1; SMN2CKS1BSKP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R MC4R 2/4885GAA 2665/4885SMN1; SMN2 1943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.